Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) went down by -0.22% from its latest closing price when compared to the 1-year high value of $73.72 and move down -63.28%, while ARWR stocks collected +2.24% of gains with the last five trading sessions. Press Release reported on 07/08/20 that Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Third Quarter Results
ARWR Market Performance
ARWR stocks went up by 2.24% for the week, with the monthly jump of 28.49% and a quarterly performance of 43.29%, while its annual performance rate touched 69.86%. The simple moving average for the period of the last 20 days is 14.09% for ARWR stocks with the simple moving average of 8.94% for the last 200 days.
Analysts’ Opinion on Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Many brokerage firms have already submitted their reports for ARWR stocks, with RBC Capital Mkts repeating the rating for ARWR shares by setting it to “Outperform”. The predicted price for ARWR socks in the upcoming period according to RBC Capital Mkts is $62 based on the research report published on May 13, 2020.
Oppenheimer, on the other hand, stated in their research note that they expect to see ARWR stock at the price of $58. The rating they have provided for ARWR stocks is “Outperform” according to the report published on May 8, 2020.
Cantor Fitzgerald gave “ Overweight” rating to ARWR stocks, setting the target price at $60 in the report published on April 15, 2020.
ARWR Stocks 23.08% Far from 50 Day Moving Average
After a stumble in the market that brought ARWR to its low price for the period of the last 52 weeks, Arrowhead Pharmaceuticals, Inc. was unable to take a rebound, for now settling with -38.75% of loss for the given period.
The stock volatility was left at 6.29%, however, within the period of a single month, the volatility rate increased by 4.33%, while the shares surge at the distance of +28.96% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +21.18% upper at the present time.
In the course of the last 5 trading sessions, ARWR went up by +2.24%, which changed the moving average for the period of 200 days to the total of +56.34% of gains for the stock in comparison to the 20-day moving average settled at $40.08. In addition, Arrowhead Pharmaceuticals, Inc. saw -28.82% in overturn over the period of a single year with a tendency to cut further losses.
ARWR Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Arrowhead Pharmaceuticals, Inc. (ARWR), starting from Anzalone Christopher Richard, who sold 100,000 shares at the price of $38.81 back on Jun 25. After this action, Rushing now owns 2,605,237 shares of Arrowhead Pharmaceuticals, Inc., valued at $3,881,017 with the latest closing price.
De Backer Marianne, the Director of Arrowhead Pharmaceuticals, Inc., bought 500 shares at the value of $31.33 during a trade that took place back on Jun 15, which means that De Backer Marianne is holding 16,500 shares at the value of $15,665 based on the most recent closing price.
ARWR Stock Fundamentals
The current profitability levels are settled at +36.25 for the present operating margin. The net margin for Arrowhead Pharmaceuticals, Inc. stands at +40.27. Total capital return value is set at 35.83, while invested capital returns managed to touch 39.69. Equity return holds the value 2.60%, with 2.10% for asset returns.